JHVEPhoto/iStock Editorial via Getty Images
Catalent (NYSE:CTLT) and Novo Nordisk Foundation received a request for more information from the Federal Trade Commission for their planned transaction. Catalent ticked lower by 0.4% in premarket trading.
On Thursday, Catalent and the Novo Nordisk Foundation each received a request for additional information and documentary materials from the FTC, according to an 8-K filing on Friday. Catalent and the Novo Nordisk are in the process of gathering information and documentary materials responsive to the second request. Catalent and Novo Holdings expect to close the merger towards the end of calendar year 2024.
In February, Catalent said it had agreed to be acquired by Novo Holdings for $16.5 billion. Novo Holdings will then sell three Catalent manufacturing sites to Novo Nordisk (NVO), which should help increase production of the company’s hugely popular weight-loss drug, Wegovy.
Reuters in February reported that the European Medicines Agency is planning to investigate whether the deal would impact drug availability.